NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2015

Primary Completion Date

November 30, 2022

Study Completion Date

March 21, 2024

Conditions

CirrhosisHepatitis B InfectionHepatitis C InfectionMetastatic Malignant Solid NeoplasmRecurrent Hepatocellular CarcinomaRecurrent Malignant Solid NeoplasmRefractory Malignant NeoplasmStage IV Hepatocellular Carcinoma AJCC v7Unresectable Solid Neoplasm

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Navitoclax

Given PO

OTHER

Pharmacological Study

Correlative studies

DRUG

Sorafenib

Given PO

DRUG

Sorafenib Tosylate

Given PO

Trial Locations (10)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

19107

Thomas Jefferson University Hospital, Philadelphia

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

55905

Mayo Clinic in Rochester, Rochester

77030

M D Anderson Cancer Center, Houston

80045

UCHealth University of Colorado Hospital, Aurora

85259

Mayo Clinic in Arizona, Scottsdale

95817

University of California Davis Comprehensive Cancer Center, Sacramento

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH